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Abstract
Background: Lipodystrophies are characterized by redistributed subcutaneous fat stores. We
previously quantified subcutaneous fat by magnetic resonance imaging (MRI) in the legs of two
patients with familial partial lipodystrophy subtypes 2 and 3 (FPLD2 and FPLD3, respectively). We
now extend the MRI analysis across the whole body of patients with different forms of
lipodystrophy.
Methods: We studied five subcutaneous fat stores (supraclavicular, abdominal, gluteal, thigh and
calf) and the abdominal visceral fat stores in 10, 2, 1, 1 and 2 female subjects with, respectively,
FPLD2, FPLD3, HIV-related partial lipodystrophy (HIVPL), acquired partial lipodystrophy (APL),
congenital generalized lipodystrophy (CGL) and in six normal control subjects.
Results:  Compared with normal controls, FPLD2 subjects had significantly increased
supraclavicular fat, with decreased abdominal, gluteal, thigh and calf subcutaneous fat. FPLD3
subjects had increased supraclavicular and abdominal subcutaneous fat, with less severe reductions
in gluteal, thigh and calf fat compared to FPLD2 subjects. The repartitioning of fat in the HIVPL
subject closely resembled that of FPLD3 subjects. APL and CGL subjects had reduced upper body,
gluteal and thigh subcutaneous fat; the APL subject had increased, while CGL subjects had
decreased subcutaneous calf fat. Visceral fat was markedly increased in FPLD2 and APL subjects.
Conclusion:  Semi-automated MRI-based adipose tissue quantification indicates differences
between various lipodystrophy types in these studied clinical cases and is a potentially useful tool
for extended quantitative phenomic analysis of genetic metabolic disorders. Further studies with a
larger sample size are essential for confirming these preliminary findings.
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Background
Adipose tissue distribution is an important biomarker
associated with metabolic risk [1]. It is important to
develop robust high-resolution quantitative non-invasive
imaging technologies for both clinical evaluation and
research applications of obesity and related metabolic dis-
orders. Magnetic resonance imaging (MRI) technology
holds a great promise as a sensitive, replicable, non-inva-
sive and non-irradiating method to image adipose tissue
quantity and distribution [1-3]. As with any quantitative
methodology, performance must be evaluated at extreme
levels of the study analytes. In this regard, lipodystrophy
syndromes represent extreme "experiments of nature" [4-
7] that can help test the limits of the resolution of MRI for
detecting and quantifying subcutaneous fat.
Lipodystrophies are a heterogeneous group of adipose tis-
sue disorders that can be either inherited or acquired [4-
8]. They are characterized by selective loss of fat from dif-
ferent anatomical regions [4,8]. Inherited lipodystrophy
syndromes include partial lipodystrophy subtypes 2 and 3
(FPLD2 and FPLD3), which are caused by heterozygous
mutations in LMNA and PPARG genes, respectively, and
congenital generalized lipodystrophy (CGL) subtypes 1
and 2, which are caused by homozygous mutations in
AGPAT2  and BSCL2  genes, respectively [4,9]. Acquired
forms of lipodystrophy include acquired partial lipodys-
trophy (APL), which is sometimes associated with hetero-
zygous mutations in the LMNB2 gene [10]. Detailed MRI
assessments of adipose tissue distribution in these diverse
lipodystrophy types have not yet been reported.
We previously reported pilot studies of adipose tissue
quantification in the lower extremity from MR images of
one patient with FPLD2 and one patient with FPLD3 [11].
While adipose tissue stores in the thigh and calf were
markedly reduced in both patients, attenuation of adipose
tissue appeared greater in the FPLD2 patient. That small
pilot study provided proof-of-principle that combining
MRI with semi-automated image analysis could reveal dif-
ferences even at the extreme low end of the range of fat
distribution [11]. We now apply this method to define
quantitative and qualitative differences in fat distribution
across a range of clinical lipodystrophy syndromes and
healthy female controls.
Methods
Clinical assessment
We studied a total of 22 female subjects: 16 were patients
with various forms of lipodystrophy and 6 were normal
healthy controls, with normal fat distribution clinically
and absence of mutations in known lipodystrophy genes.
The lipodystrophy patients included 10 subjects with
FPLD2, two with FPLD3, one with human immunodefi-
ciency virus (HIV)-associated partial lipodystrophy
(HIVPL), one with acquired partial lipodystrophy (APL)
and two with congenital generalized lipodystrophy
(CGL). All patients consented to provide their medical
history, underwent physical examination and provided
fasting blood samples. All subjects gave informed consent
and the University of Western Ontario Institutional
Review Board approved the protocol (#11244).
Bioimpedance analysis
Bioimpedance analysis (BIA) measurements were deter-
mined using the BC-418 Segmental Body Composition
Analyzer (Tanita, Arlington Heights, IL) which provided
percent fat estimates for the total body and lower extrem-
ities. The intra-observer coefficient of variation for BIA
measurements was 4.5%.
Molecular screening
DNA was prepared from peripheral blood leukocytes
(Puregene, Gentra Systems, Minneapolis, MN). DNA
sequences of all subjects were screened for mutations in
candidate lipodystrophy genes, namely LMNA, PPARG,
LMNB2,  AGPAT2  and  BSCL2, which are causative for
FPLD2, FPLD3, APL and the two forms of CGL, respec-
tively (MIM 150330, 601487, 150341, 603100, 606158).
Amplified and purified genomic DNA fragments were
sequenced using reported exon-specific primers for LMNA
[12], PPARG  [5,13], LMNB2 [10], BSCL2  and AGPAT2
[14]. Electropherograms were then analyzed using
Sequence Navigator v.1.0.1 (Applied Biosystems, Missis-
sauga, ON).
Magnetic resonance imaging
We used scanning and raw MR image acquisition param-
eters as reported previously [11]. MRI scans were per-
formed on a 1.5T GE MR Medical system (Model: Signa
Excite). A neurovascular array coil was used to image the
supraclavicular region and an 8-channel receive-only
torso array coil was used to image other body regions.
Validation of adipose tissue quantification method
In order to validate the developed adipose tissue quantifi-
cation method [11] against a reference anatomical stand-
ard, MR and cryosection abdominal images of the male
cadaver from the Visible Human Project were analyzed
(Figure 1) [15]. Both image types were obtained from the
Visible Human online database [16]. Cryosection images
were available as 1 mm thick transaxial slices spanning the
entire body. MR images of the visible human were availa-
ble as sagittal slice images. Five transaxial images were
selected from the abdominal cryosection images for adi-
pose tissue analysis. These images were anatomically allo-
cated using the following reference points: 1) upper lobe
of the liver, 2) upper lobe of the left kidney, 3) upper lobe
of the right kidney, 4) lower lobe of the left kidney, 5)
lower lobe of the right kidney. In order to obtain the cor-BMC Medical Imaging 2007, 7:3 http://www.biomedcentral.com/1471-2342/7/3
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responding MR transaxial images, the abdominal MR sag-
ittal image stack was imported into the ImageJ 1.34 n
program [17] and re-sliced into 1 mm thick transaxial
slice images using the Stack-Reslice tool. Corresponding
MR images were selected based on the same anatomical
allocations discussed above.
After obtaining the images above, subcutaneous adipose
tissue was quantified in both MR and corresponding cry-
osection images using the method developed in our labo-
ratory [11]. The Pearson correlation coefficient was used
to test both intra-observer variation among duplicate
blinded MRI and cryosection subcutaneous adipose tissue
measurements and also to test the accuracy of fat quanti-
fication in MR images in comparison to the anatomically
matched cryosection images.
Adipose tissue quantification
Subcutaneous adipose tissue was quantified from MR
images of: 1) mid-line sagittal sections of the supraclavic-
ular region; and transverse sections of the: 2) abdomen at
L4 level; 3) gluteal region at the level of the femoral heads;
4) mid-thigh level; and 5) mid-calf level. Supraclavicular
fat pad quantification required standardized manual trun-
cation of the raw MR fat signal superiorly and inferiorly
along horizontal planes extended parallel to the plane of
the scan from the tip of the subject's nose and to the bot-
tom of the twelfth spinal vertebra, respectively (Figure 2).
Quantification of subcutaneous adipose and visceral fat at
the abdomen-L4 level and gluteal region also required
manual truncation: fat adjacent to the viscera within the
peritoneal compartment was outlined (Figure 3). Quanti-
fication of visceral adipose tissue in abdomen-L4 and glu-
teal segments was then calculated by subtracting the
subcutaneous adipose tissue signal from total subcutane-
ous and visceral signals and dividing by the total thresh-
old signal (Figure 3). Semi-automated quantification was
performed using image analysis software employing Con-
nected Threshold Grower and Voxel Counter tools [11].
Statistical analysis
All statistical analyses were performed using SAS version
9.2 (SAS Institute, Cary, NC). Mean values between
FPLD2 and control groups were compared using student
t-tests. A nominal P-value < 0.05 was chosen as the thresh-
old for significance for all statistical comparisons. Pearson
correlation coefficients were calculated between percent
fat in the lower limb as determined by BIA and MRI meth-
ods. The Pearson correlation coefficient was also used to
test variation among duplicate blinded subcutaneous adi-
pose tissue measurements made by the same observer on
different days in the supraclavicular, abdominal-subcuta-
neous, abdominal-visceral and gluteal MRI sections
(intra-observer variability) and also to test inter-observer
variation for the same samples, analyzed by a different
observer on different days.
Results
Clinical, biochemical and anthropometric data
Table 1 shows demographic baseline clinical and bio-
chemical data for study subjects. The mean values for the
normal control subjects would not meet any threshold for
the National Cholesterol Education Program (NCEP) cri-
teria for the metabolic syndrome. In contrast, mean val-
Validation of adipose tissue quantification method against an anatomical reference standard from the Visible Human Project Figure 1
Validation of adipose tissue quantification method against an anatomical reference standard from the Visible 
Human Project. The image on the left is an abdominal transaxial MR image allocated at the upper liver lobe of the Visible 
Human Male [15, 16]. The image on the right is the corresponding cryosection image obtained from the same subject. Quanti-
fied percent subcutaneous adipose tissue values for both images are reported below the respective image.BMC Medical Imaging 2007, 7:3 http://www.biomedcentral.com/1471-2342/7/3
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Quantification of percent adipose tissue in upper back/shoulder region Figure 2
Quantification of percent adipose tissue in upper back/shoulder region. For a given sagittal mid-slice MRI image, both 
the total volume and the subcutaneous (sc) fat volumes were selected using the Connected Threshold Grower tool. Subcuta-
neous adipose tissue (sc) to be quantified was pre-determined by truncating the raw MR image with upper and lower black-
colored lines which extend horizontally from the tip of the nose to the back of the neck and horizontally from the lowermost 
point of the twelfth spinal vertebra (illustrated by the yellow lines in the top image). The corresponding volumes were deter-
mined using the Voxel Counter tool. The percent subcutaneous adipose tissue was calculated for by dividing the voxel count 
determined for the sc fat by the total voxels for the slice.BMC Medical Imaging 2007, 7:3 http://www.biomedcentral.com/1471-2342/7/3
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Quantification of percent adipose tissue in abdomen-L4 region Figure 3
Quantification of percent adipose tissue in abdomen-L4 region. For a given transaxial MR image, both the total vol-
ume and the total subcutaneous and connected visceral (sc + visc) fat volumes were selected using the Connected Threshold 
Grower tool. Subcutaneous adipose tissue (sc) cannot be obtained directly due to software limitation, and is selected for by 
manually eliminating visceral signals present in (sc + visc) images Their corresponding volumes were determined using the 
Voxel Counter tool. The percent subcutaneous adipose tissue was calculated for by dividing the voxel count determined for 
the sc fat by the total voxels for the slice. The percent visceral adipose tissue was calculated for by subtracting the sc fat voxel 
count from that of sc + visc and then dividing the value obtained by the total voxels for the slice. Solid lines in the figure repre-
sent direct automated attainment of threshold image via ImageJ program. Dotted lined represent indirect attainment of thresh-
old image, requiring manual modification.BMC Medical Imaging 2007, 7:3 http://www.biomedcentral.com/1471-2342/7/3
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ues, or single values for those disease categories with only
a single patient, indicate that all lipodystrophy patient
groups would meet the NCEP criteria for the metabolic
syndrome [18].
Genetic analysis
FPLD2 subjects were each heterozygous for the LMNA
R482Q missense mutation [12]. FPLD3 subjects were het-
erozygous for the PPARG F388L mutation [13]. No muta-
tions were found in any of the candidate genes in the
genome of the HIVPL subject. The APL subject was heter-
ozygous for the LMNB2 R215Q missense mutation [10].
The CGL subjects were each homozygous for the
frameshift mutation in BSCL2 [14].
Validation of adipose tissue quantification method
Subcutaneous adipose tissue values were obtained from 5
transaxial locations in the Visible Human male [15,16] for
both MR and cryosection images (Figure 1). The intra-
observer correlation coefficients, determined by compar-
ing duplicate blinded measurements of percent subcuta-
neous fat from the 5 locations, were 0.996 and 0.999 for
the MR and cryosection image sets, respectively. The cor-
relation coefficient was 0.999 for the comparison of mean
percent subcutaneous adipose tissue values obtained from
the MR images and matching cryosection images.
Intra- and inter-observer correlations for quantitative MRI 
analysis
Intra- and inter-observer correlations for analysis of the
mid-calf and mid-thigh were determined previously [11].
Analysis of adipose tissue in the newly investigated com-
partments, namely the supraclavicular, abdominal-subcu-
taneous, abdominal-visceral and gluteal sections, was
conducted by two independent observers. Intra- and inter-
observer correlation coefficients were determined by com-
paring two replicates from eight study subjects. The intra-
observer correlation coefficients were, on average, 0.994,
0.999, 0992, and 0.999 for the supraclavicular, abdomi-
nal-subcutaneous, abdominal-visceral and gluteal sec-
tions, respectively. The inter-observer correlation
coefficients were, on average, 0.997, 0.995, 0.992, and
0.998 for the supraclavicular, abdominal-subcutaneous,
abdominal-visceral and gluteal sections, respectively.
Correlation of percent fat in thigh determined by BIA and 
MRI
Figure 4 shows a significant correlation between percent
fat as determined in the thigh by MRI and by BIA (P <
0.0001), suggesting that BIA can serve as a rough surrogate
for MRI quantification of subcutaneous fat. Although the
correlation coefficient of 0.52 was significant, it is still rel-
atively modest, indicating that the variables are somewhat
interrelated, but not interchangeable. Interestingly,
almost all the data points for lipodystrophy subjects fell
below the line of best fit, suggesting that MRI quantifica-
tion of subcutaneous fat might systematically underesti-
mate total fat content (including intramuscular fat), as
estimated by BIA in these subjects.
MRI quantification of regional fat stores
Figure 5 summarizes the fat quantification experiments.
Contrasts of either "increased" or "decreased" fat stores
are with reference to the normal ranges for control sub-
jects. Table 2 shows that FPLD2 subjects had significantly
increased supraclavicular subcutaneous fat and abdomen-
L4 visceral fat, with significantly decreased abdomen-L4,
Table 1: Clinical and biochemical profile of 22 female subjects
normal controls FPLD2 FPLD3 HIVPL APL CGL
number 6 10 2 1 1 2
age (years) 40 ± 16 48 ± 16 36 ± 15 41 64 40 ± 1
BMI (kg/m2) 26.4 ± 6.73 24.3 ± 2.07 33.9 ± 0.72 28.3 20.3 23.0 ± 0.08
Molecular genetic basis of disease None LMNA R482Q (all) PPARG F388L (all) None LMNB2 R215G BSCL2 frameshift (both)
diabetes 0/6 3/10 1/2 0/1 1/1 2/2
hypertension 1/6 5/10 2/2 1/1 1/1 1/1
dyslipidemia 0/6 10/10 2/2 1/1 1/1 1/1
total cholesterol (mM) 4.41 ± 0.54 4.76 ± 1.13 3.80 ± 0.43 5.37 3.63 4.08 ± 0.78
triglycerides (mM) 1.08 ± 0.63 2.62 ± 1.09 1.84 ± 1.27 6.29 2.82 2.13 ± 0.83
LDL cholesterol (mM) 2.36 ± 0.33 2.59 ± 1.11 2.42 ± 0.59 ND 1.50 2.09 ± 0.69
HDL cholesterol (mM) 1.56 ± 0.45 1.01 ± 0.29 0.88 0.50 0.85 1.04 ± 0.44
fasting blood glucose (mM) 4.71 ± 1.14 6.01 ± 1.74 8.35 ± 0.21 5.30 12.6 6.65 ± 1.34
insulin (uIU/mL) 13.8 ± 13.7 19.0 ± 14.6 29.5 ± 14.9 27.8 63.6 140 ± 130
apolipoprotein B (g/L) 0.71 ± 0.12 0.90 ± 0.18 ND ND 0.75 0.99 ± 0.43
apolipoprotein A-I (g/L) 1.51 ± 0.38 1.25 ± 0.28 ND ND 1.06 1.04 ± 0.21
systolic blood pressure (mm/Hg) 119 ± 19.2 127 ± 13.7 134 ± 8.49 126 108 113 ± 7
diastolic blood pressure (mm/Hg) 70 ± 11.7 73.5 ± 8.9 71.0 ± 8.5 82 56.0 75.0 ± 7.1
waist circumference (cm) 87.0 ± 19.2 87.5 ± 7.9 118 ± 17 107 118 77.5 ± 0.7
Abbreviations: FPLD2 and FPLD3, Dunnigan variety familial partial lipodystrophy types 2 and 3, respectively; HIVPL, Human immunodeficiency virus 
partial lipodystrophy; APL, acquired partial lipodystrophy; CGL, congenital generalized lipodystrophyBMC Medical Imaging 2007, 7:3 http://www.biomedcentral.com/1471-2342/7/3
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gluteal, thigh and calf subcutaneous fat compared with
control subjects (unpaired t-tests, all P < 0.01).
Both FPLD2 and FPLD3 subjects had increased supracla-
vicular fat (Figure 5a), reflecting the increase in upper
body fat observed clinically [19]. The patient with HIVPL
also had increased supraclavicular fat, comparable to the
FPLD3 patients (Figure 5a). In contrast, supraclavicular fat
in the APL subject was not increased and CGL subjects had
reduced supraclavicular fat (Figure 5a), consistent with
generalized depletion of body fat [4,20].
FPLD2 and FPLD3 subjects had clear disparities in abdo-
men-L4 subcutaneous fat (Figure 5b), with a significant
decrease and no decease in FPLD2 and FPLD3 subjects,
respectively. HIVPL, APL and CGL subjects had varying
amounts of subcutaneous adipose tissue at the abdomen-
L4 level: no decrease for the HIVPL subject, but markedly
decreased for the APL and CGL subjects. Again, the HIVPL
patient most closely resembled the FPLD3 subject.
Further disparities between FPLD2 and FPLD3 were seen
for visceral adipose tissue at the abdomen-L4 level; vis-
ceral fat content was the opposite of the subcutaneous fat
distribution at this level (Figure 5c), with a significant
increase and no increase in the FPLD2 and FPLD3 sub-
jects, respectively. Thus FPLD2 subjects have more severe
depletion of abdominal subcutaneous fat and more pro-
nounced accumulation of visceral fat than FPLD3 sub-
jects. The HIVPL patient had marginally increased visceral
adipose tissue, again comparable to the FPLD3 subjects.
The APL subject had markedly increased visceral adipose
tissue while the CGL subjects showed a range of visceral
fat.
Gluteal subcutaneous fat distribution was comparable to
the abdomen-L4 distribution (Figure 5d). Gluteal fat in
the FPLD2 and FPLD3 subjects was decreased and not
decreased, respectively (Figure 5d). The HIVPL subject
again closely resembled the FPLD3 subjects (Figure 5d).
APL and CGL subjects both showed decreased gluteal fat,
with APL having the lowest value (Figure 5d).
The most consistently altered fat depot across all lipodys-
trophy types was decreased subcutaneous thigh fat (Figure
5e). Similar to other subcutaneous depots, FPLD2 subjects
had pronounced depletion of subcutaneous thigh fat,
while FPLD3 subjects had less depletion of subcutaneous
thigh fat (Figure 5e). A descending trend of adipose tissue
amount was observed for subjects with HIVPL, APL and
CGL, respectively (Figure 5e). Subcutaneous adipose tis-
sue in HIVPL subject most resembled that of FPLD3 sub-
jects. CGL subjects had nearly no subcutaneous adipose
tissue in this region and harbored some of the lowest val-
ues from these experiments (Figure 5e).
The pattern of subcutaneous fat distribution in the mid-
calf was very similar to that observed in the mid-thigh
(Figure 5f). FPLD2 subjects had greater depletion of calf
fat than FPLD3 subjects (Figure 5f). The HIVPL patient
had reduced fat comparable to the quantity seen in FPLD3
Correlation of percent fat from mid-thigh obtained by BIA  and MRI Figure 4
Correlation of percent fat from mid-thigh obtained 
by BIA and MRI. These values were obtained across all 
subjects in the study. Filled circles represent the control 
group, while non-filled circles represent the lipodystrophic 
group. The Pearson correlation coefficient was 0.52 (P < 
0.0001).
Table 2: Comparison of regional mean ± standard deviation percent fat in 10 FPLD2 subjects and 6 normal control subjects
Fat Depot FPLD2 Control P-value
Subcutaneous
Supraclavicular 7.34 ± 3.40 4.10 ± 2.42 0.049
Abdomen – L4 8.27 ± 4.98 30.9 ± 8.00 < 0.0001
Gluteal 12.4 ± 7.70 29.8 ± 10.4 0.0004
Thigh 12.7 ± 6.70 38.0 ± 9.80 < 0.0001
Calf 4.34 ± 4.94 25.4 ± 3.50 < 0.0001
Visceral
Abdomen – L4 35.4 ± 8.60 8.81 ± 7.15 < 0.0001BMC Medical Imaging 2007, 7:3 http://www.biomedcentral.com/1471-2342/7/3
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Percent subcutaneous and visceral adipose tissue values in different body segments of patients and healthy controls Figure 5
Percent subcutaneous and visceral adipose tissue values in different body segments of patients and healthy 
controls. Shaded region represents the range of adipose tissue values of the normal control group. Horizontal line and whisk-
ers represent the mean and standard deviation of adipose tissue percentages seen in normal controls. Horizontal line in FPLD2 
plots represents the mean value of adipose tissue in these subjects. (a) Percent subcutaneous adipose tissue in the upper back 
and shoulders. (b) Percent subcutaneous adipose tissue in the abdomen-L4 region. (c) Percent visceral adipose tissue in the 
abdomen-L4 region. (d) Percent subcutaneous adipose tissue in the gluteal region. (e) Percent subcutaneous adipose tissue in 
the thighs. Values for left and right thigh are plotted as two separate points for each subject. (f) Percent subcutaneous adipose 
tissue in the calves. Values for left and right calf are plotted as two separate points for each subject.BMC Medical Imaging 2007, 7:3 http://www.biomedcentral.com/1471-2342/7/3
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(Figure 5f). In contrast to all other lipodystrophic subjects
studied, the APL subject had increased adipose tissue in
the calves (Figure 5f). CGL subjects showed the greatest
decrease in calf fat (Figure 5f).
Discussion
In this study of all female subjects we have shown that
MRI analysis with quantification of fat depots can reveal
differences between patients with various forms of lipod-
ystrophy. Evaluating lipodystrophy patients allowed for
assessment of the lower limits of resolution of the
method. The main findings include: 1) demonstration of
significant differences from controls in FPLD2 subjects,
with increased suprvaclavicular and visceral fat and
decreased subcutaneous abdominal, gluteal, thigh and
calf fat; 2) confirmation of the subjective clinical impres-
sion of differences between FPLD2 and FPLD3 subjects,
such as no increase in visceral fat, no decrease in abdo-
men-L4 subcutaneous fat and less dramatic depletion of
subcutaneous gluteal, thigh and calf fat in FPLD3 com-
pared with FPLD2 subjects; 3) fat repartitioning in the
HIVPL subject resembled the FPLD3 subjects; 4) reduced
subcutaneous fat in the upper body, gluteal region and
thigh, in both APL and CGL subjects, with increased and
decreased calf fat in APL and CGL subjects, respectively;
and 5) consistently reduced fat in the mid-thigh across the
various lipodystrophy types, suggesting that this analyte
could help distinguishing whether a form of lipodystro-
phy might be present in a patient with in whom the clini-
cal diagnosis is unclear.
Sampling measurements of adipose tissue in specific body
regions was an important approach for the identification
of adipose tissue distribution differences among lipodys-
trophic patients. Qualitatively, MR images as well as exter-
nal phenotypes of different lipodystrophic subjects hint to
the loss of fat is specific body regions, such as loss of fat in
the extremities and general abdominal-visceral fat accu-
mulation that is seen in the FPLD subjects. Whole-body
measurements of adipose tissue [21,22], is a potential
next step in similar future research. While valuable in its
ability to represent total body fat, we chose to implement
a sampling approach instead of whole-body fat quantifi-
cation in this pilot study to help focus on the quantitative
investigation of adipose tissue distribution.
We observed very high intra- and inter-observer correla-
tion values for the combination of methods, and further-
more, validated the method against an anatomical
reference standard. In addition to reproducibility, the
described methods yield results quickly and accurately,
with minimal user intervention. While the correlation
coefficient of percent fat values found by MRI and BIA was
statistically significant, the r of 0.52 indicated only mod-
est correlation, suggesting that the two determinations are
not interchangeable. BIA appears to measure total limb
fat, including both subcutaneous and intramuscular fat,
while MRI measures only subcutaneous fat. Acquisition of
such values from a larger number of patients with various
lipodystrophy subtypes would verify the results observed
here. Future application of this quantification method, or
another [23-27], may include quantification of fat depots
for "garden variety" obesity, metabolic syndrome or dia-
betes. This approach might also be applicable to quantify
metabolically important substrata of fat.
Widespread application of MRI-based fat quantification
would require the development of standards with respect
to regions surveyed, anatomical landmarks, number of
measurements, etc – similar to the consensus standards
agreed upon for carotid intima-media thickness measure-
ments using ultrasound. Regional distribution could be
an additional MRI analyte that could be considered
together with other intermediate traits in subjects with
FPLD or even common metabolic syndrome. Quantifica-
tion of fat depots using MRI and appropriate image anal-
ysis software could provide complementary analytes for
research and perhaps eventually for the diagnosis and
monitoring of interventions.
Conclusion
In summary, we report the expanded use of MRI and
image analysis software employing Connected Threshold
Grower and Voxel Counter tools to quantify fat depots at
multiple sites in patients with several different molecular
forms of lipodystrophy. The measurements confirmed the
clinical impression that FPLD2 and FPLD3 differ with
respect to the extent of subcutaneous fat loss; specifically,
subcutaneous fat loss below the umbilicus and visceral fat
accumulation in FPLD2 are both greater than in FPLD3.
Increasing the sample size of subjects with other forms of
lipodystrophy will allow for statistical comparisons. These
tools can be applied and might prove useful in quantita-
tive phenotype analysis of other forms of lipodystrophy
and in less extreme disorders of fat redistribution or repar-
titioning, such as "garden variety" or common obesity,
insulin resistance, or type 2 diabetes.
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